new art laboratories





NADAL® COVID-19 S1-NAb Test

For the qualitative detection of potentially neutralising antibodies against SARS-CoV-2 in human whole blood, serum or plasma samples.

Neutralising antibodies against SARS-CoV-2

The effectiveness of vaccines against coronavirus SARS-CoV-2 lies between 65 % and 95 %*. The detection of neutralising antibodies can determine whether a vaccine has been successful. Following a vaccination or an infection with coronavirus, various antibodies are produced by the immune system. However, only some of the antibodies formed have a neutralising effect, i.e. they prevent the virus from entering the host cell. Neutralising antibodies block the spike protein on the surface of the virus, preventing it from binding to the host cell's ACE2 receptors and thus protecting against a severe course of infection with COVID-19.

These potentially neutralising antibodies against the S1 subunit of the SARS-CoV-2 spike protein can be detected using a rapid test.

NADAL® COVID-19 S1-NAb Test

The test serves as an aid in determining whether an immune response to the S1 subunit of the SARS-CoV-2 spike protein has occurred. Antibodies can be detected against vaccines that trigger an immune response against the S1 subunit of the spike protein, such as those from **BioNTech/Pfizer**,

Moderna®, AstraZeneca, Johnson&Johnson and Sinovac Life Sciences. The test procedure is not automated and requires no special training or qualifications. The NADAL® COVID-19 S1-NAb Test is intended for professional use.

Your benefits at a glance:

- √ Fingerstick blood sample
- ✓ Can be carried out using whole blood (venous or fingerstick), serum or plasma
- ✓ Results in just 2 steps
- ✓ Results within 10 minutes
- ✓ Detection of potentially neutralising antibodies against SARS-CoV-2 following vaccination or infection
- ✓ High sensitivity and specificity
- ✓ Storage at room temperature possible






Test procedure



Human host cell ACE2-receptor SARS-CoV-2 If no neutralising antibodies against the SARS-CoV-2 virus

 If no neutralising antibodies against the SARS-CoV-2 virus are present, the receptor binding domain (RBD) located on the spike protein (S-protein) can bind to and enter the ACE2 receptors on human host cells



Neutralising antibodies bind to the receptor binding domain on the spike protein of the virus, preventing the virus from 'docking' with the host cell.

Result interpretation





NADAL® COVID-19 S1-NAb Test

For the qualitative detection of potentially neutralising antibodies against SARS-CoV-2

Product	Sample material	Sensitivity*	Specificity**	Product code	Pack size
NADAL® COVID-19 S1-NAb test cassette	Whole blood, serum or plasma samples	>99.9 %	99.5 %	243301N-20	20 tests per pack

Kit includes test cassettes • capillary tubes • buffer • instructions for use

- * Sensitivity and specificity were determined by comparison with a microneutralisation assay with samples from vaccinated individuals, recovered individuals and also healthy, unvaccinated individuals.
- ** Specificity was confirmed using 208 serum samples from July 2019 (prior to the COVID-19 outbreak).

Our customer service team is on hand to answer any questions you may have by telephone, via email or in a personal consultation. For details on your local sales office and regional free phone numbers, visit www.nal-vonminden.com.





Rev01.01/XX0705en0009